Bluejay Diagnostics says SYMON II study ‘progressing as planned’

Bluejay continues to advance its Symphony platform, including the company’s lead product candidate for the rapid measurement of Interleukin-6 to support sepsis risk assessment and critical-care decision making. The company confirmed that its SYMON II clinical study is progressing as planned, with ongoing site activities and enrollment consistent with internal timelines. Data generated from this study is intended to support the company’s regulatory strategy. Due to regulatory considerations, including FDA requirements and disclosure constraints, Bluejay may be limited in its ability to release detailed clinical data prior to regulatory submission; however, the company intends to provide appropriate updates in accordance with the analysis of primary end points with the study’s statistical analysis plan.